Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-01-22
2008-01-22
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S227100, C536S023720, C536S023400, C435S320100
Reexamination Certificate
active
10630070
ABSTRACT:
The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.
REFERENCES:
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4683136 (1987-07-01), Milich et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4818527 (1989-04-01), Thornton et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5726011 (1998-03-01), Milich et al.
patent: 5990085 (1999-11-01), Ireland et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6406705 (2002-06-01), Davis et al.
patent: 6602705 (2003-08-01), Barnett et al.
patent: 6887464 (2005-05-01), Coleman et al.
patent: 2003/0054337 (2003-03-01), Birkett
patent: 2003/0099668 (2003-05-01), Bachmann et al.
patent: 2003/0138769 (2003-07-01), Birkett
patent: 2003/0175296 (2003-09-01), Brown et al.
patent: 2003/0175863 (2003-09-01), Birkett
patent: 2003/0185854 (2003-10-01), Zavala et al.
patent: 2003/0185858 (2003-10-01), Birkett
patent: 2003/0198645 (2003-10-01), Page et al.
patent: 2003/0202982 (2003-10-01), Birkett
patent: 2004/0054139 (2004-03-01), Page et al.
patent: 2004/0146524 (2004-07-01), Lyons et al.
patent: 2004/0152876 (2004-08-01), Birkett
patent: 2004/0156864 (2004-08-01), Birkett
patent: 2004/0219164 (2004-11-01), Coleman et al.
patent: 7252300 (1995-10-01), None
patent: WO 95/27083 (1995-10-01), None
patent: WO 9527083 (1995-10-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 00/46365 (2000-08-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO/0198333 (2001-12-01), None
patent: WO 0214478 (2002-02-01), None
patent: WO 02/13765 (2002-12-01), None
Zlotnick, A. et al. Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: Implications for morphgenesis and organization of encapsidated RNA (1997) Proc. Natl. Acad. Sci. 94: 9556-9561.
Gallina, A. et al A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids (1989) Journal of Virology, 63(11): 4645-4652.
Pumpens, P. et al. Hepatitis core particles as a universal display model : a structure-function basis for development (1999) FEBS Letters, vol. 442:1-6.
Ulrich, R. et al. Core particles of hepatitis B virus as carrier for foreign epitopes (1998) Advances in Virus Research, vol. 50:141-182.
Galibert et al. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence (1982) J. Virol. 41:51-65.
Koschel, M. et al., Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutation that allow capsid formation (1999) Journal of Virology, 73(3): 2153-2160.
SCORE sequence search results 4, 10 (2006).
Chang et al., “Phenotypic Mixing between Different Hepadnarvirus Nucleocapsid Proteins Reveals C Protein Dimerizaton To BecisPreferential,” (1994) J. Virol. 5225-5231.
Pumpens and Grens (2001) “HBV Core Particles as a Carrier for B Cell/T Cell Epitopes,” Intervirology 44:98-114.
Jegerlehner et al. “A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses,”(2002) Vaccine 20:3104.
Anderson and Young, Quantitative Filter Hybridization,in Nucleic Acid Hybridization[1985].
Smith and Waterman (1981) “Comparison of Biosequences,” Adv. Appl. Math. 2: 482-489.
Needleman and Wunsch (1970) “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” J. Mol. Biol. 48: 443-453.
Pearson and Lipman (1988) “Improved tools for biological sequence comparison,” Proc. Natl. Acad. Sci. U.S.A. 85:2444.
Sambrook et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, pp. 9.31-9.58, 1989.
Sambrook, et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, pp. 7.39-7.52, 1989.
GenBank Accession No. NKVLC2 printed Jul. 16, 1999.
GenBank Accession No. NP—040993 printed Dec. 8, 2002.
Winter and Milstein (1991) “Man-made antibodies,” Nature 349:293-299.
Böttcher et al. (1997) “Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy,” Nature 386:88-91.
Conway et al. (1997) “Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy,” Nature 386:91-94.
Salfeld et al. (1989) “Antigenic Determinants and Functional Domains in Core Antigen and e Antigen from Hepatitis B Virus,” J Virol. 63:798-808.
Schodel et al. (1992) “The Position of Heterologous Epitopes Inserted in Hepatitis B Virus Core Particles Determines Their Immunogenicity,” J Virol. 66:106-114.
Milich et al. (1995) “The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety,” Ann NY Acad Sci. 754:187-201.
Pumpens et al. (1995) “Hepatitis B Virus Core Particles as Epitope Carriers,” Intervirology 38:63-74.
Clarke et al. (1987) “Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein,” Nature 330:381-384.
Schodel et al. (1994) “Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes,” J Exp Med. 180:1037-1046.
Schodel et al. “Immunization with Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Antigen Epitopes Protects Mice AgainstPlasmodium yoeliiChallenge,” (1997) Behring Inst Mitt. 114-119.
Milich et al. (1997) “Role of B cells in antigen presentation of the hepatitis B core,” Proc Natl Acad Sci USA 94:14648-14653.
Kratz et al. (1999) “Native display of complete foreign protein domains on the surface of hepatitis B virus capsids,” Proc Natl Acad Sci USA 96:1915-1920.
Chen et al. (2000) “Nondeletional T-Cell Receptor Transgenic Mice: Model for the CD4+ T-Cell Repertoire in Chronic Hepatitis B Virus Infection,” J. Virol. 74:7587-7599.
Lazdina et al. (2001) “Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells,” J Virol. 75:6367-6374.
Cao et al. (2001) “Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model,” J Virol. 75:6359-6366.
Anttila et al. (1998) “Avidity of IgG forStreptococcus pneumoniaeType 6B and 23F Polysaccharides in Infants Primed with Pneumococcal Conjugates and Boosted with Polysaccharide or Conjugate Vaccines,” J Infect Dis. 177:1614-1621.
Arad et al. (2000) “Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation,” Nat Med. 6:414-421.
Visvanathan et al. (2001) “Inhibition of Bacterial Superantigens by Peptides and Antibodies,” Infect Immunol. 69:875-884.
DeVelasco et al. (1994) “Adjuvant Quil A improves protection in mice and enhaces opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines,” Vaccine 12:1419-1422.
Koletzki et al. (1997) “Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments,” J Gen Virol. 78:2049-2053.
Smiley and Minion (1993) “Enhanced readthrough of opal (UGA) stop codons and production ofMycoplasma pneumoniaeP1 epitopes inEscherichia coli,” Gene 134:33-40.
GenBank Accession No. NM 009778 printed Apr. 2003.
Dempsey et al. (1996) “C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity,” Science 271:348-350.
Tedder et al. (1994) “The CD19/CD21 signal transduction complex of B lymphocytes,” Immunol Today 15:437-442.
GenBank Accession No. X65453
Billaud Jean-Noel
Milich David R.
Medlen & Carroll LLP
Mosher Mary E.
Vaccine Research Institute of San Diego
LandOfFree
Rodent hepatitis B virus core proteins as vaccine platforms... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rodent hepatitis B virus core proteins as vaccine platforms..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rodent hepatitis B virus core proteins as vaccine platforms... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3953856